Investments in pre-IPO Ginkgo Bioworks and Paragon 28 are complete
Paragon 28: +67% Ginkgo Bioworks: -18%
Paragon 28 is developing cutting-edge technologies for foot and ankle problems. The investment in this company was first introduced on our platform in December 2020, back then a single share was $8.23 (after the split). The price of the shares upon the closing of the investment on May 10 was $13.75. Investors’ return excluding commissions: +67%.
Ginkgo Bioworks is a leading cell and gene therapy company. The stock in this company was first introduced on the UT platform in October 2020, then a single share was $138.6.
In September 2021, Ginkgo went public by merging with a SPAC and its shares were converted into the shares of a new public company. As a result, the price of investors’ share at the pre-IPO stage was $2.82.
The share price closed on May 10 at $2.30. The result of the investment, excluding commissions, was -18%.
You can invest in other pre-IPO companies on the UT website.